Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is poised for continued growth and success, with a strong portfolio of precision diagnostics and radiopharmaceutical products that address unmet needs in the cardiology and oncology markets. The recent approval of Pylarify, a PSMA imaging agent for prostate cancer, and the acquisition of Evergreen Theragnostics and the FDA's approval of its pipeline asset LNTH-2501 are all catalysts for future growth. Additionally, the company's strong financial performance in the first quarter of 2026 and its focus on strategic partnerships and diversification leave it well-positioned for future success.

Bears say

Lantheus Holdings is facing potential issues with third-party manufacturing for their radiopharmaceutical assets, causing delays in potential FDA approval and revenue contribution. Additionally, their Alzheimer's pipeline, while promising in the long term, is not expected to make a significant impact for the next 2-3 years and is dependent on the availability of therapeutic agents. The recent approval of PSMA-PET formulation is a positive development, but the company is facing pricing pressure and margin dilution, which could affect their financial performance in the near term.

Lantheus Holdings (LNTH) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 6 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.